List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7186146/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	ERCC6, a member of a subfamily of putative helicases, is involved in Cockayne's syndrome and preferential repair of active genes. Cell, 1992, 71, 939-953.	28.9	698
2	Defective Transcription-Coupled Repair in Cockayne Syndrome B Mice Is Associated with Skin Cancer Predisposition. Cell, 1997, 89, 425-435.	28.9	301
3	UV-induced ubiquitination of RNA polymerase II: a novel modification deficient in Cockayne syndrome cells Proceedings of the National Academy of Sciences of the United States of America, 1996, 93, 11586-11590.	7.1	290
4	Genome sequencing and comparison of two nonhuman primate animal models, the cynomolgus and Chinese rhesus macaques. Nature Biotechnology, 2011, 29, 1019-1023.	17.5	284
5	The Cockayne syndrome B protein, involved in transcription-coupled DNA repair, resides in an RNA polymerase II-containing complex. EMBO Journal, 1997, 16, 5955-5965.	7.8	232
6	Molecular Analysis of Mutations in the CSB(ERCC6) Gene in Patients with Cockayne Syndrome. American Journal of Human Genetics, 1998, 62, 77-85.	6.2	145
7	Quantitative Proteomics and Metabolomics Analysis of Normal Human Cerebrospinal Fluid Samples*. Molecular and Cellular Proteomics, 2010, 9, 2063-2075.	3.8	127
8	Cockayne syndrome: defective repair of transcription?. EMBO Journal, 1997, 16, 4155-4162.	7.8	106
9	The Effect of Preanalytical Factors on Stability of the Proteome and Selected Metabolites in Cerebrospinal Fluid (CSF). Journal of Proteome Research, 2009, 8, 5511-5522.	3.7	102
10	Double Mutants of <i>Saccharomyces cerevisiae</i> with Alterations in Global Genome and Transcription-Coupled Repair. Molecular and Cellular Biology, 1996, 16, 496-502.	2.3	99
11	Biochemical and Biological Characterization of Wild-type and ATPase-deficient Cockayne Syndrome B Repair Protein. Journal of Biological Chemistry, 1998, 273, 11844-11851.	3.4	98
12	Assembly of the Escherichia coli RuvABC resolvasome directs the orientation of Holliday junction resolution. Genes and Development, 1999, 13, 1861-1870.	5.9	85
13	Functional interactions between the Holliday junction resolvase and the branch migration motor of Escherichia coli. EMBO Journal, 1998, 17, 1838-1845.	7.8	77
14	Analytical techniques for multiplex analysis of protein biomarkers. Expert Review of Proteomics, 2020, 17, 257-273.	3.0	60
15	The Impact of Delayed Storage on the Measured Proteome and Metabolome of Human Cerebrospinal Fluid. Clinical Chemistry, 2011, 57, 1703-1711.	3.2	59
16	Quantitative Matrix-Assisted Laser Desorption Ionizationâ^'Fourier Transform Ion Cyclotron Resonance (MALDIâ^'FT-ICR) Peptide Profiling and Identification of Multiple-Sclerosis-Related Proteins. Journal of Proteome Research, 2009, 8, 1404-1414.	3.7	51
17	Inflammation biomarker discovery in Parkinson's disease and atypical parkinsonisms. BMC Neurology, 2020, 20, 26.	1.8	51
18	Analysis of 953 Human Proteins from a Mitochondrial HEK293 Fraction by Complexome Profiling. PLoS ONE, 2013, 8, e68340.	2.5	51

#	Article	IF	CITATIONS
19	Bridging the translational innovation gap through good biomarker practice. Nature Reviews Drug Discovery, 2017, 16, 587-588.	46.4	48
20	Data Sharing Under the General Data Protection Regulation. Hypertension, 2021, 77, 1029-1035.	2.7	47
21	Uncovering a Predictive Molecular Signature for the Onset of NASH-Related Fibrosis in a Translational NASH Mouse Model. Cellular and Molecular Gastroenterology and Hepatology, 2018, 5, 83-98.e10.	4.5	44
22	Mass Spectrometry for Identification, Monitoring, and Minimal Residual Disease Detection of M-Proteins. Clinical Chemistry, 2020, 66, 421-433.	3.2	41
23	A CHO mutant, UV40, that is sensitive to diverse mutagens and represents a new complementation group of mitomycin C sensitivity. Mutation Research DNA Repair, 1996, 363, 209-221.	3.7	34
24	From biomarker strategies to biomarker activities and back. Drug Discovery Today, 2010, 15, 121-126.	6.4	29
25	Mammalian nucleotide excision repair and syndromes. Biochemical Society Transactions, 1997, 25, 309-315.	3.4	26
26	Phenotypic heterogeneity in nucleotide excision repair mutants of rodent complementation groups 1 and 4. Mutation Research DNA Repair, 1997, 383, 91-106.	3.7	25
27	Molecular Portrait of the Progestagenic and Estrogenic Actions of Tibolone: Behavior of Cellular Networks in Response to Tibolone. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 973-983.	3.6	25
28	An integrated framework of personalized medicine: from individual genomes to participatory health care. Croatian Medical Journal, 2012, 53, 301-303.	0.7	25
29	Multiple Myeloma Minimal Residual Disease Detection: Targeted Mass Spectrometry in Blood vs Next-Generation Sequencing in Bone Marrow. Clinical Chemistry, 2021, 67, 1689-1698.	3.2	24
30	Evaluation of cyclooxygenase oxylipins as potential biomarker for obesity-associated adipose tissue inflammation and type 2 diabetes using targeted multiple reaction monitoring mass spectrometry. Prostaglandins Leukotrienes and Essential Fatty Acids, 2020, 160, 102157.	2.2	21
31	NMR and Pattern Recognition Can Distinguish Neuroinflammation and Peripheral Inflammation. Journal of Proteome Research, 2011, 10, 4428-4438.	3.7	20
32	The proteomic toolbox for studying cerebrospinal fluid. Expert Review of Proteomics, 2012, 9, 165-179.	3.0	20
33	Biosynthetic homeostasis and resilience of the complement system in health and infectious disease. EBioMedicine, 2019, 45, 303-313.	6.1	20
34	Minocycline Effects on the Cerebrospinal Fluid Proteome of Experimental Autoimmune Encephalomyelitis Rats. Journal of Proteome Research, 2012, 11, 4315-4325.	3.7	19
35	Integrated Chemometrics and Statistics to Drive Successful Proteomics Biomarker Discovery. Proteomes, 2018, 6, 20.	3.5	19
36	Towards a routine application of Top-Down approaches for label-free discovery workflows. Journal of Proteomics, 2018, 175, 12-26.	2.4	17

#	Article	IF	CITATIONS
37	Cerebrospinal fluid monocyte chemoattractant protein 1 correlates with progression of Parkinson's disease. Npj Parkinson's Disease, 2020, 6, 21.	5.3	17
38	Inflammatory cytokine oncostatin M induces endothelial activation in macro- and microvascular endothelial cells and in APOE*3Leiden.CETP mice. PLoS ONE, 2018, 13, e0204911.	2.5	15
39	Plasma C-Peptide and Risk of Developing Type 2 Diabetes in the General Population. Journal of Clinical Medicine, 2020, 9, 3001.	2.4	14
40	Affimers as an alternative to antibodies for protein biomarker enrichment. Protein Expression and Purification, 2020, 174, 105677.	1.3	13
41	Clonotypic Features of Rearranged Immunoglobulin Genes Yield Personalized Biomarkers for Minimal Residual Disease Monitoring in Multiple Myeloma. Clinical Chemistry, 2021, 67, 867-875.	3.2	12
42	Metabolomics-Based Screening of Inborn Errors of Metabolism: Enhancing Clinical Application with a Robust Computational Pipeline. Metabolites, 2021, 11, 568.	2.9	11
43	Understanding the increased risk of infections in diabetes: innate and adaptive immune responses in type 1 diabetes. Metabolism: Clinical and Experimental, 2021, 121, 154795.	3.4	11
44	Oncostatin M reduces atherosclerosis development in APOE*3Leiden.CETP mice and is associated with increased survival probability in humans. PLoS ONE, 2019, 14, e0221477.	2.5	10
45	The funhouse mirror: the I in personalised healthcare. Life Sciences, Society and Policy, 2021, 17, 1.	3.2	10
46	Site-Specific, Platform-Based Conjugation Strategy for the Synthesis of Dual-Labeled Immunoconjugates for Bimodal PET/NIRF Imaging of HER2-Positive Tumors. Bioconjugate Chemistry, 2022, 33, 530-540.	3.6	10
47	Quantitative multiplex profiling of the complement system to diagnose complementâ€mediated diseases. Clinical and Translational Immunology, 2020, 9, e1225.	3.8	9
48	Escherichia coli RuvBL268S: a mutant RuvB protein that exhibits wild- type activities in vitro but confers a UV-sensitive ruv phenotype in vivo. Nucleic Acids Research, 1999, 27, 1275-1282.	14.5	7
49	Functional interactions of Mycobacterium leprae RuvA with Escherichia coli RuvB and RuvC on holliday junctions 1 1Edited by M. Yaniv. Journal of Molecular Biology, 2000, 301, 839-850.	4.2	6
50	The future of protein biomarker research in type 2 diabetes mellitus. Expert Review of Proteomics, 2019, 16, 105-115.	3.0	6
51	Evaluation of chitotriosidase as a biomarker for adipose tissue inflammation in overweight individuals and type 2 diabetic patients. International Journal of Obesity, 2019, 43, 1712-1723.	3.4	6
52	Network signatures link hepatic effects of anti-diabetic interventions with systemic disease parameters. BMC Systems Biology, 2014, 8, 108.	3.0	5
53	Alterations in the hepatic transcriptional landscape after RNAi mediated ApoB silencing in cynomolgus monkeys. Atherosclerosis, 2015, 242, 383-395.	0.8	5
54	Limited impact of impaired awareness of hypoglycaemia and severe hypoglycaemia on the inflammatory profile of people with type 1 diabetes. Diabetes, Obesity and Metabolism, 2020, 22, 2427-2436.	4.4	5

#	Article	IF	CITATIONS
55	Semi-Quantitative Multiplex Profiling of the Complement System Identifies Associations of Complement Proteins with Genetic Variants and Metabolites in Age-Related Macular Degeneration. Journal of Personalized Medicine, 2021, 11, 1256.	2.5	5
56	Proteomic profiling of striatal tissue of a rat model of Parkinson's disease after implantation of collagenâ€encapsulated human umbilical cord mesenchymal stem cells. Journal of Tissue Engineering and Regenerative Medicine, 2020, 14, 1077-1086.	2.7	4
57	Qualitative evaluation of coronary atherosclerosis in a large cohort of young and middle-aged Dutch tissue donors implies that coronary thrombo-embolic manifestations are stochastic. PLoS ONE, 2018, 13, e0207943.	2.5	3
58	Biomarker Research and Development for Coronavirus Disease 2019 (COVID-19): European Medical Research Infrastructures Call for Global Coordination. Clinical Infectious Diseases, 2021, 72, 1838-1842.	5.8	3
59	Common Variants Associated With OSMR Expression Contribute to Carotid Plaque Vulnerability, but Not to Cardiovascular Disease in Humans. Frontiers in Cardiovascular Medicine, 2021, 8, 658915.	2.4	3
60	Clinical biomarker innovation: when is it worthwhile?. Clinical Chemistry and Laboratory Medicine, 2019, 57, 1712-1720.	2.3	2
61	Biomarkers in the drug development process: Report from workshop discussions. Regulatory Toxicology and Pharmacology, 2008, 52, 75-76.	2.7	1
62	Sharing lessons learnt across European cardiovascular research consortia. Drug Discovery Today, 2020, 25, 787-792.	6.4	1
63	Fasting Proinsulin Independently Predicts Incident Type 2 Diabetes in the General Population. Journal of Personalized Medicine, 2022, 12, 1131.	2.5	1